Veterinary CRO And CDMO Market to Grow with a CAGR of 8.90% through 2030
Rising
focus on companion animal health and expanding pipeline of veterinary vaccines
and biologics, is expected to drive the Global Veterinary CRO And
CDMO Market growth in the forecast period, 2026-2030
According to
TechSci Research report, “Veterinary CRO And CDMO Market – Global Industry
Size, Share, Trends, Competition Forecast & Opportunities, 2030F”,
the Global Veterinary CRO And CDMO Market stood at USD 5.78 Billion in
2024 and is expected to reach USD 9.65 Billion by 2030 with a CAGR of 8.90% during
the forecast period. The
Global Veterinary CRO and CDMO Market is witnessing dynamic transformation as
the complexity of veterinary therapeutics continues to evolve across species.
The surge in pet ownership and the rise in pet insurance have increased
expectations around advanced and tailored veterinary treatments, driving
pharmaceutical companies to outsource specialized tasks to contract partners.
CDMOs are seeing growing demand for flexible batch production, sterile
injectable manufacturing, and packaging solutions tailored to varied dosage
forms used in animal healthcare.
Emerging
trends are redefining how veterinary R&D is conducted. Artificial
intelligence and machine learning are being introduced to enhance predictive
modeling, protocol design, and patient selection in veterinary clinical trials.
Cloud-based data platforms now enable real-time collaboration between sponsors,
veterinarians, and trial monitors, reducing delays and human error. Companies
are exploring novel drug delivery systems for animals, such as transdermal
patches and implantable devices, prompting CDMOs to develop new formulation
capabilities. Environmental sustainability is also shaping contract
manufacturing strategies, with growing interest in greener production methods,
waste reduction, and animal-friendly testing alternatives. As veterinary innovation
expands to include oncology, chronic pain, and behavioral health treatments,
contract research and manufacturing providers are adjusting their service
models to accommodate these emerging therapeutic domains.
The
market presents notable growth opportunities, particularly in underpenetrated
segments like aquaculture and exotic animal health, which require highly
specialized research expertise. Biopharmaceutical firms developing novel
biologics and companion animal therapeutics are increasingly seeking CDMOs with
high-containment capabilities and cold chain logistics. CROs focusing on
pharmacokinetics, toxicology, and epidemiological surveillance are gaining
attention due to the growing intersection between animal and public health,
especially within the “One Health” framework. As more countries adopt
regulatory harmonization and digital submission portals, market entry barriers
for contract players are expected to lower. This shift will enable emerging
companies with innovative platforms, localized facilities, or modular service
offerings to compete effectively in the global landscape. With rising investor
interest, strategic collaborations, and public-private partnerships expanding,
the Veterinary CRO and CDMO Market is poised for sustained, diversified growth
beyond 2030.
Browse over XX
market data Figures spread through XX Pages and an in-depth TOC on
"Global Veterinary CRO And CDMO Market”
The Global Veterinary
CRO And CDMO Market is segmented into animal, service, application, regional
distribution, and company.
Based on the Application,
Medical Devices emerged as the fastest growing segment in the Global Veterinary
CRO And CDMO Market during the forecast period. This is driven by the rising
adoption of innovative diagnostic and therapeutic technologies in animal healthcare.
With increased demand for advanced tools such as implantable devices,
monitoring systems, surgical instruments, and diagnostic imaging equipment
tailored for veterinary use, animal health companies are increasingly turning
to CROs and CDMOs for product design, testing, and regulatory support. These
medical devices require rigorous validation, biocompatibility studies, and
field evaluations to ensure safety and efficacy across various animal species. Veterinary
CROs are offering specialized expertise in preclinical studies, usability
testing, and device performance assessments, while CDMOs provide services for
precision manufacturing, prototyping, and packaging.
Based
on the Region, Asia-Pacific emerged as the fastest growing region in the Global
Veterinary CRO And CDMO Market during
the forecast period. This is driven by rising investments in pharmaceutical
manufacturing infrastructure, favorable government policies promoting local
production, and a surge in contract manufacturing demand for veterinary
biologics and generic products. Emerging markets in the region are offering
attractive opportunities for global CDMOs to set up facilities or form
strategic partnerships with local players. The increasing focus on livestock
productivity and disease control, especially in agriculture-driven economies,
is fueling demand for vaccines, feed additives, and injectable therapeutics,
thus boosting contract development and manufacturing activities. The adoption
of new technologies, such as continuous manufacturing and single-use
bioprocessing systems, is helping Asian CDMOs compete on a global scale by
delivering high-quality, scalable, and compliant production services. As regulatory
frameworks across countries like China and India continue to evolve and align
with global standards, the ease of doing business for contract service
providers is expected to improve significantly.
Major
companies operating in Global Veterinary CRO And CDMO Market are:
- Fortrea
Holdings Inc.
- Charles
River Laboratories International, Inc.
- Clinvet
(Pty) Ltd.
- KLIFOVET
GmbH
- Veterinary
Research Management, Inc.
- VETSPIN
SRL
- Inotiv,
Inc.
- IDEXX
Laboratories, Inc.
- Vetio
Animal Health
- TriRx
Pharmaceutical Services, LLC
Download Free Sample Report
Customers can
also request for 10% free customization on this report
“The Global Veterinary CRO and CDMO
Market is expanding due to the rising demand for end-to-end lifecycle
management services beyond initial product approval, as veterinary
pharmaceutical companies increasingly depend on contract partners to support
reformulations, shelf-life extensions, labeling updates, and compliance with
evolving global regulatory requirements. This trend is driven by the need to
sustain competitive advantage, maximize product lifespan, and adapt existing
formulations to meet changing therapeutic needs or market preferences. CDMOs
and CROs offering expertise in post-marketing surveillance, pharmacovigilance,
and regulatory strategy are becoming critical partners in ensuring long-term
commercial success. Their ability to provide flexible, scalable, and
region-specific solutions positions them as key enablers of continued
innovation and market expansion.,” said Mr. Karan Chechi, Research
Director of TechSci Research, a research-based management consulting firm.
“Veterinary CRO And CDMO
Market - Global Industry Size, Share, Trends, Opportunity, and Forecast,
Segmented By Animal (Companion Animals, Livestock Animals), By Service
(Discovery, Development, Manufacturing, Packaging & Labeling, Market
Approval & Post Marketing), By Application (Pharmaceuticals, Biologics,
Medical Devices, Others), By Region and Competition, 2020-2030F”,
has evaluated the future growth potential of Global Veterinary CRO And CDMO
Market and provides statistics & information on market size, structure and
future market growth. The report intends to provide cutting-edge market
intelligence and help decision makers take sound investment decisions. Besides,
the report also identifies and analyzes the emerging trends along with
essential drivers, challenges, and opportunities in Global Veterinary CRO And
CDMO Market.
Contact
TechSci
Research LLC
420
Lexington Avenue, Suite 300,
New York,
United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com